Abbott Labs: Q4 in line with expectations
(CercleFinance.com) - Abbott Laboratories has reported Q4 2018 adjusted EPS for continuing operations of 81 cents, in line with the consensus, for revenues that are up 2.
3% at 7.8 billion dollars (+6.4% in organic terms).
For the full year, the healthcare group reported adjusted EPS that is up 15.2% at 2.88 dollars, in its target range of 2.87-2.89 dollars, for sales growth of 11.6% at 30.6 billion dollars (+7.3% in organic terms).
In the year ahead, Abbott expects adjusted EPS of 3.15 dollars to 3.25 dollars, meaning double-digit growth in the middle of this range, for organic growth of 6.5% at 7.5%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
3% at 7.8 billion dollars (+6.4% in organic terms).
For the full year, the healthcare group reported adjusted EPS that is up 15.2% at 2.88 dollars, in its target range of 2.87-2.89 dollars, for sales growth of 11.6% at 30.6 billion dollars (+7.3% in organic terms).
In the year ahead, Abbott expects adjusted EPS of 3.15 dollars to 3.25 dollars, meaning double-digit growth in the middle of this range, for organic growth of 6.5% at 7.5%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.